FDA reviewers question new Xarelto use; Shire predicts EPS at top end of forecast; Forest asks FDA for pediatric extension on Namenda;

@FiercePharma: Valeant, Mylan, and Actavis eye Pfizer's brand-new generics unit for buyout: Reuters. Story | Follow @FiercePharma

@TracyStaton: Top story at FiercePharma Monday: Look for an M&A scramble as pharma cash chases higher prices. Story | Follow @TracyStaton

@EricPFierce: India's Aurobindo is looking for more sterile injectable capacity and Actavis has some in the EU for sale. Deal? Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Chinese corruption probe expands as officials detain former Sinopharm exec. More | Follow @CarlyHFierce

> Johnson & Johnson ($JNJ) could face an uphill climb for a new indication for its bloodthinner Xarelto, with FDA reviewers skeptical of its benefits. Report

> Shire ($SHPG) expects 2013 earnings growth to bump up against the top end of its forecasts, aided by a strategy shift and cost cuts. Report

> Forest Laboratories ($FRX) asked the FDA to extend its market exclusivity on the Alzheimer's drug Namenda, under the agency's pediatric-study program. Release

> Vivus ($VVUS), which makes the new Qsymia weight-loss pill, will collaborate with health insurer Aetna on a weight-loss program comprising drugs and lifestyle interventions. Release

> Colombia's Biotoscana inked a deal to buy a Brazilian pharma group, United Medical, to broaden its product portfolio and extend its commercial reach in South America. Release

> Portland, OR-based Galena Biopharma ($GALE) and India's Dr. Reddy's have teamed up to develop Galena's gastric cancer treatment NeuVax for sale in India. Release

> Mississippi-based Pharma Pac, which specializes in cream and ointment formulas, laid off 75 employees, or almost half its workforce. Report

Medical Device News

@FierceMedDev: JPM 2014: GlySure CEO hits SF to advance the company's ICU glucose monitoring device.  | Follow @FierceMedDev

@MarkHFierce: Phillips is in trouble with the FDA, in part, for conducting a recall and not informing regulators about the details. Warning letter | Follow @MarkHFierce

@MichaelGFierce: Roche's delivery method 'shuttles' Alzheimer's drugs past blood-brain barrier. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Hate getting shots? You might be able to try this painless drug injector soon. Article | Follow @EmilyWFierce

@GalenMoore: Covidien puts Almeida's JPM '14 words into practice with a brace of deals in emerging markets. Report | Follow @GalenMoore

> St. Jude's CEO is still betting on renal denervation, despite Medtronic's setback. Story

> Carlyle Group reportedly nears deal to grab J&J's Ortho Clinical Diagnostics unit. Item

> Qiagen and Exosome pair up for a Dx development deal. News

Biotech News

@FierceBiotech: Jazz bets up to $397M on Aerial's narcolepsy drug. Story | Follow @FierceBiotech

@JohnCFierce: I predict that today we'll move from deal talk to bold CEO projections at JPMorgan 2014. It is a fun spectator sport. | Follow @JohnCFierce

@DamianFierce: For its next trick, Moderna splits in two with $20M cancer venture. News | Follow @DamianFierce

@EmilyMFierce: Investigators find a way to keep stem cells' options open until they're needed. More | Follow @EmilyMFierce

> Bristol-Myers looks to rival Gilead for the key to conquering the hep C market. More

> Allergan CEO preps multibillion-dollar deal spree to swell pipeline. News

> Regeneron, Bayer reach for the old Eylea magic with combo AMD deal. Article

> AstraZeneca's Soriot faces off against skeptics, preaches late-stage R&D revival. Coverage

Biotech Research News

> Embryonic-like stem cells created from frozen tissue of Alzheimer's patients. More

> Scientists capture key protein structures that could aid malaria vaccine design. News

> Low doses of cancer drug prevent Type 1 diabetes in mice. Story

> Investigators find a way to keep stem cells' options open until they're needed. Article

> Mimetas, Galapagos partner on organs-on-chip technology. Piece

> European industry-academic partnership seeks miRNA therapies for neurodegenerative diseases. Item

Pharma Manufacturing News

> 11 compounders tell the FDA to bring it on. Report

> Aurobindo is looking to buy API plants from Actavis. More

> China corruption probe takes a turn into domestic drug distribution business. News

> Ranbaxy manufacturing drama continues with FDA action on API plant. Story

> McKesson recalibrates its EU strategy after Celesio deal nosedives. Article

> Wockhardt hires a new compliance exec in the face of FDA bans. Item

And Finally... High-tech facial reconstructions aren't just for humans anymore; they're going to the dogs (and cats). Report (sub. req.)

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.